TY - JOUR
T1 - Introduction and utilization of high priced HCV medicines across Europe; implications for the future
AU - de Bruijn, Winnie
AU - Ibáñez, Cristina
AU - Frisk, Pia
AU - Bak Pedersen, Hanne
AU - Alkan, Ali
AU - Vella Bonanno, Patricia
AU - Brkicic, Ljiljana S.
AU - Bucsics, Anna
AU - Dedet, Guillaume
AU - Eriksen, Jaran
AU - Fadare, Joseph O.
AU - Fürst, Jurij
AU - Gallego, Gisselle
AU - Godói, Isabella P.
AU - Guerra Júnior, Augusto A.
AU - Gürsöz, Hakki
AU - Jan, Saira
AU - Jones, Jan
AU - Joppi, Roberta
AU - Kerman, Saim
AU - Laius, Ott
AU - Madzikwa, Newman
AU - Magnússon, Einar
AU - Maticic, Mojca
AU - Markovic-Pekovic, Vanda
AU - Massele, Amos
AU - Ogunleye, Olayinka
AU - O'Leary, Aisling
AU - Piessnegger, Jutta
AU - Sermet, Catherine
AU - Simoens, Steven
AU - Tiroyakgosi, Celda
AU - Truter, Ilse
AU - Thyberg, Magnus
AU - Tomekova, Kristina
AU - Wladysiuk, Magdalena
AU - Vandoros, Sotiris
AU - Vural, Elif H.
AU - Zara, Corinne
AU - Godman, Brian
N1 - Publisher Copyright:
© 2016 de Bruijn, Ibáñez, Frisk, Bak Pedersen, Alkan, Vella Bonanno, Brkicic, Bucsics, Dedet, Eriksen, Fadare, Fürst, Gallego, Godói, Guerra Júnior, Gürsöz, Jan, Jones, Joppi, Kerman, Laius, Madzikwa, Magnússon, Maticic, Markovic-Pekovic, Massele, Ogunleye, O'Leary, Piessnegger, Sermet, Simoens, Tiroyakgosi, Truter, Thyberg, Tomekova, Wladysiuk, Vandoros, Vural, Zara and Godman.
PY - 2016/7/22
Y1 - 2016/7/22
N2 - Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors (PIs) boceprevir (BCV) and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will continue to rise with new treatments including sofosbuvir, which now include interferon free regimens. Objective: Assess the uptake of BCV and TVR across Europe from a health authority perspective to offer future guidance on dealing with new high cost medicines. Methods: Cross-sectional descriptive study of medicines to treat HCV (pegIFN, ribavirin, BCV and TVR) among European countries from 2008 to 2013. Utilization measured in defined daily doses (DDDs)/1000 patients/quarter (DIQs) and expenditure in Euros/DDD. Health authority activities to influence treatments categorized using the 4E methodology (Education, Engineering, Economics and Enforcement). Results: Similar uptake of BCV and TVR among European countries and regions, ranging from 0.5 DIQ in Denmark, Netherlands and Slovenia to 1.5 DIQ in Tayside and Catalonia in 2013. However, different utilization of the new PIs vs. ribavirin indicates differences in dual vs. triple therapy, which is down to factors including physician preference and genotypes. Reimbursed prices for BCV and TVR were comparable across countries. Conclusion: There was reasonable consistency in the utilization of BCV and TVR among European countries in comparison with other high priced medicines. This may reflect the social demand to limit the transmission of HCV. However, the situation is changing with new curative medicines for HCV genotype 1 (GT1) with potentially an appreciable budget impact. These concerns have resulted in different prices across countries, with their impact on budgets and patient outcomes monitored in the future to provide additional guidance.
AB - Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors (PIs) boceprevir (BCV) and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will continue to rise with new treatments including sofosbuvir, which now include interferon free regimens. Objective: Assess the uptake of BCV and TVR across Europe from a health authority perspective to offer future guidance on dealing with new high cost medicines. Methods: Cross-sectional descriptive study of medicines to treat HCV (pegIFN, ribavirin, BCV and TVR) among European countries from 2008 to 2013. Utilization measured in defined daily doses (DDDs)/1000 patients/quarter (DIQs) and expenditure in Euros/DDD. Health authority activities to influence treatments categorized using the 4E methodology (Education, Engineering, Economics and Enforcement). Results: Similar uptake of BCV and TVR among European countries and regions, ranging from 0.5 DIQ in Denmark, Netherlands and Slovenia to 1.5 DIQ in Tayside and Catalonia in 2013. However, different utilization of the new PIs vs. ribavirin indicates differences in dual vs. triple therapy, which is down to factors including physician preference and genotypes. Reimbursed prices for BCV and TVR were comparable across countries. Conclusion: There was reasonable consistency in the utilization of BCV and TVR among European countries in comparison with other high priced medicines. This may reflect the social demand to limit the transmission of HCV. However, the situation is changing with new curative medicines for HCV genotype 1 (GT1) with potentially an appreciable budget impact. These concerns have resulted in different prices across countries, with their impact on budgets and patient outcomes monitored in the future to provide additional guidance.
KW - Boceprevir
KW - Cross national drug utilization study
KW - Demand-side measures
KW - Hepatitis C
KW - Introduction new medicines
KW - Sofosbuvir
KW - Telaprevir
UR - http://www.scopus.com/inward/record.url?scp=84981505057&partnerID=8YFLogxK
U2 - 10.3389/fphar.2016.00197
DO - 10.3389/fphar.2016.00197
M3 - Article
AN - SCOPUS:84981505057
SN - 1663-9812
VL - 7
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
IS - JUL
M1 - 197
ER -
